The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Chapter 1 – Introduction
Chapter 2 – Trends in drug delivery dealmaking
Chapter 3 – Leading drug delivery deals
Chapter 4 – Bigpharma drug delivery deals
Chapter 5 – Drug delivery partnering contracts directory
Chapter 6 – Drug delivery dealmaking by technology type
– Baxter International
– Bristol-Myers Squibb
– Eli Lilly
– Endo Pharmaceuticals
– Forest Laboratories
– Johnson & Johnson
– Kyowa Hakko Kirin
– Merck & Co
– Merck KGaA
– Mitsubishi Tanabe
– Warner Chilcott